Related Experiment Video
Updated: Jul 10, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
GABA A/Bz receptor subtypes as targets for selective drugs
F Da Settimo1, S Taliani, M L Trincavelli
1Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Targeting specific gamma-aminobutyric acid type A (GABA(A)) receptor subtypes with novel ligands offers potential for treating neurological disorders. Developing subtype-selective benzodiazepine site (BzR) ligands may lead to treatments with fewer side effects.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Gamma-aminobutyric acid type A (GABA(A)) receptors are key inhibitory neurotransmitter receptors in the brain.
- These receptors comprise various subunit isoforms, influencing distinct physiological effects.
- The benzodiazepine site (BzR) on GABA(A) receptors is a target for allosteric modulators.
Purpose of the Study:
- To review the development of subtype-selective ligands for GABA(A) receptors.
- To explore structure-activity relationships for benzodiazepine site (BzR) ligands.
- To highlight the therapeutic potential of alpha-selective GABA(A) receptor modulators.
Main Methods:
- Review of existing literature on GABA(A) receptor pharmacology.
- Analysis of structure-activity relationships of benzodiazepine site (BzR) ligands.
- Categorization of ligands based on chemical structure and selectivity profiles.
Main Results:
- Different alpha subunit-containing GABA(A) receptors are associated with distinct functions (sedation, anxiolysis, cognition).
- Ligand selectivity can be achieved through differential affinity or efficacy at receptor subtypes.
- Structure-activity relationships guide the design of selective BzR ligands.
Conclusions:
- Alpha-selective GABA(A) receptor ligands hold promise for treating anxiety, sleep disorders, convulsions, and memory deficits.
- Targeting specific receptor subtypes may minimize off-target side effects.
- Further research into subtype-selective ligands can advance GABAergic system-associated pharmacotherapy.
More Related Videos
07:51Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
Published on: November 14, 2014
11:57Using an α-Bungarotoxin Binding Site Tag to Study GABA A Receptor Membrane Localization and Trafficking
Published on: March 28, 2014
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...